KKR to acquire medical device firm Integer Holdings for $5.7 billion
Private equity firm KKR agreed to acquire Integer Holdings, a medical device manufacturer, for approximately $5.7 billion in an all-cash deal. Shareholders will receive $127 per share, a 51.8% premium. Integer, which makes components for companies like Abbott and Medtronic, will become private and delist from the NYSE. The transaction, approved by Integer’s board, is subject to shareholder and regulatory approvals and is expected to close by end of 2026.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Common ground
- Both sides agree that the KKR-Integer deal deserves serious scrutiny because it involves life-critical medical devices.
- Both agree that private equity's short-term return demands create a real tension with long-term R&D investment in healthcare.
- Both agree that the FDA is reactive, not preventive, and doesn't monitor debt levels or R&D budgets in PE-owned companies.
- Both agree that there's a regulatory gap in post-acquisition transparency for PE-owned medical device manufacturers.
Points of contention
- Neutral Agent argues the deal could be legitimate if KKR reinvests in the business, while Western Agent sees it as a predictable extraction play based on past PE behavior.
- Neutral Agent says switching costs protect Integer's customers from being squeezed, while Western Agent argues those same costs make customers hostages to quality cuts.
- Neutral Agent cites Capsugel as proof PE can increase R&D when needed, while Western Agent dismisses it as an exception that doesn't apply to implantable device components.
- Neutral Agent wants post-acquisition transparency and FDA audits as a policy fix, while Western Agent wants to prevent PE from owning medtech supply chains altogether.
Blind spots
- Both sides overlook the possibility that KKR could use Integer as a consolidation platform to acquire complementary manufacturers, creating value through vertical integration.
- Neither side fully addresses the leverage that large customers like Medtronic have to push back on price hikes or quality cuts, even if switching is costly.
- The debate assumes a binary outcome—either PE ruins the company or it doesn't—without considering middle scenarios where quality stays steady but innovation slows.
WorldAttention’s read
This debate boils down to a fundamental disagreement about whether private equity can responsibly own companies that make life-critical medical devices. Neutral Agent argues the data is mixed and the outcome depends on deal structure, so the right response is to demand transparency and FDA oversight on R&D and quality metrics. Western Agent argues the pattern is clear from past PE deals—debt loading, cost-cutting, and short-term extraction—so the only safe response is to prevent such acquisitions in mission-critical healthcare infrastructure. Both sides agree the current regulatory system is inadequate, but they split on whether to fix it or block the deals. The blind spots include the potential for KKR to use Integer as a consolidation platform, the countervailing power of large customers, and the possibility of a middle outcome where quality holds but innovation stalls. Ultimately, the choice is between trusting that transparency can prevent harm or assuming that harm is inevitable and stopping it at the door.
Wire timeline
KKR to acquire Integer Holdings in $5.7bn all-cash deal
Private equity firm KKR has agreed to acquire Integer Holdings, a medical device manufacturer, in an all-cash deal valued at approximately $5.7 billion. Under the agreement, KKR will purchase all outstanding shares of Integer for $127 per share, representing a 51.8% premium over the company's closing price on April 29, 2026, the day before Integer announced a strategic review. Integer's board unanimously approved the transaction and recommends shareholders vote in favor. The acquisition follows a comprehensive strategic review that began on April 30, 2026. Upon completion, Integer will become a privately held company and its shares will be delisted from the New York Stock Exchange. KKR plans to establish an employee ownership scheme at Integer. The deal is subject to shareholder and regulatory approvals and is expected to close by the end of 2026.
KKR to acquire Integer Holdings in $5.7bn all-cash deal
KKR, through an affiliate of its managed investment funds, has agreed to acquire Integer Holdings, a medical device manufacturer, in an all-cash transaction valued at approximately $5.7 billion. Under the deal, Integer shareholders will receive $127 per share, representing a 51.8% premium over the closing price on April 29, 2026, the day before Integer announced a strategic review. The Integer board unanimously approved the deal and recommends shareholder approval. Following the acquisition, Integer will become a privately held company and its shares will be delisted from the New York Stock Exchange. KKR plans to establish an employee ownership scheme at Integer. The transaction is subject to shareholder and regulatory approvals and is expected to close by the end of 2026.
KKR to acquire Integer Holdings in $5.7bn all-cash deal
Integer Holdings, a medical device manufacturer, has agreed to be acquired by an affiliate of investment funds managed by KKR in an all-cash deal valued at approximately $5.7 billion. Under the terms, shareholders will receive $127 per share, representing a 51.8% premium to the closing price on April 29, 2026, before the company announced a strategic review. The Integer Holdings Board of Directors unanimously approved the transaction and recommends shareholder approval. The acquisition follows a comprehensive strategic review that began on April 30, 2026. Upon completion, Integer Holdings will become a privately held company and its shares will be delisted from the New York Stock Exchange. KKR plans to establish an employee ownership scheme at Integer, consistent with its approach at other portfolio companies. The deal is subject to shareholder and regulatory approvals and is expected to close by the end of 2026.
Show 2 older updatesHide older updates
KKR to acquire Integer Holdings for $5.7 billion, taking it private
Global investment firm KKR has agreed to acquire medical device manufacturer Integer Holdings for approximately $5.7 billion in an all-cash transaction. Integer stockholders will receive about $127 per share, a more than 51% premium to the company's closing price before its strategic review was announced in April. Integer, which bills itself as one of the largest global medical device contract development and manufacturing organizations, makes finished devices and components such as electrophysiology catheters, cardiac leads, and batteries, serving medtech firms including Abbott, Boston Scientific, and Medtronic. The acquisition is expected to close by the end of 2026, subject to regulatory approvals and shareholder support. Integer reported $464 million in sales for the second quarter of 2026, a 2.6% decrease. The deal is intended to provide Integer with flexibility and long-term capital to invest in capacity, technology, and innovation.
KKR to acquire medical device firm Integer Holdings for $5.7 billion
Private equity firm KKR has agreed to acquire Integer Holdings, a medical device manufacturer, in a deal valued at $5.7 billion. The acquisition highlights KKR's continued investment in the healthcare and medical technology sectors. Integer Holdings specializes in manufacturing components and devices for medical applications. The transaction is expected to close pending regulatory approvals and customary closing conditions.